ADCs and TCE in SCLC Therapy: The Beginning of a New Era?

ADCs and TCE in SCLC Therapy: The Beginning of a New Era?

The therapeutic landscape for small cell lung cancer (SCLC) has remained stationary for decades, with chemotherapy representing the sole treatment strategy, with a modest survival benefit. The addition of immune checkpoint inhibitors (ICIs) to standard first-line chemotherapy for SCLC was a consider...

Full description

Saved in:
Bibliographic Details
Main Authors: Paola Muscolino, Fausto Omero, Desirèe Speranza, Carla Infurna, Silvana Parisi, Vincenzo Cianci, Massimiliano Berretta, Alessandro Russo, Mariacarmela Santarpia
Format: Article
Language:English
Published: MDPI AG 2025-04-01
Series:Current Oncology
Subjects:
SCLC
ICIs
TCE
ADCs
immunotherapy
ifinatamab deruxtecan
Online Access:https://www.mdpi.com/1718-7729/32/5/261
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items